Witty's Successor: The Shortlist
This article was originally published in Scrip
Executive Summary
"The board will now start a formal search for a successor and will consider internal and external candidates for the role," said GlaxoSmithKline PLC's chair Sir Philip Hampton, and the games begin.
You may also be interested in...
GSK Management Shake Up Ahead Of New CEO Sees Hussain Out, AZ's Miels In
"Succession processes are challenging for everyone involved and, unfortunately, it is rare that all of those involved stay with the company," stated GSK's out-going CEO Andrew Witty, as Abbas Hussain decides to leave the company having lost out on the top job, which went to Emma Walmsley. His successor will be AstraZeneca's Luke Miels.
Will GSK’s Walmsley Be Feared As ‘Witty But Worse’?
The announcement that Emma Walmsley is to take over from Sir Andrew Witty as CEO of GSK is surprising in more ways than one.
GSK’s New CEO Designate Walmsley Fortifies Volume Growth Strategy
GSK’s new CEO will be Emma Walmsley, currently head of its Consumer Healthcare division. While some investors had wished for a company outsider with a ‘fresh pair of eyes’, GSK’s board decided to go for the best of both worlds: an insider with plenty of non-pharma experience.